Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies
| Authors | |
|---|---|
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Medicine |
| MU Faculty or unit | |
| Citation | |
| web | https://journals.lww.com/md-journal/FullText/2020/06050/Anti_M_llerian_hormone_as_an_ovarian_reserve.42.aspx |
| Doi | http://dx.doi.org/10.1097/MD.0000000000020523 |
| Keywords | anti-Mullerian hormone; fertility; muscular dystrophy; myotonic dystrophy; ovarian reserve |
| Description | Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Mullerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7ng/mL; range 0 - 4.9ng/mL) compared with age-matched healthy controls (P<.01). AMH levels were similar between patients and controls in terms of females with MD2 (P=.98), FSHD (P=.55) and cDMD (P=.60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD. |
| Related projects: |